SBIR/STTR Research Award
Preclinical Studies of PG70 LEAPS Peptide Vaccines for Rheumatoid Arthritis
Award amount
$224,999Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CEL-SCI CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GBEVFWHXBEE7
- Solicitation number
- PA13-234
- Topic code
- NIAMS
Research abstract
DESCRIPTION (provided by applicant): Currently, FDA-licensed pharmaceuticals used to treat rheumatoid arthritis (RA) focus largely on alleviation of symptoms, either through pain management, general immunosuppression, or by antagonizing cytokines such as TNF-?. Despite recent advances in biologic therapies, these treatments do not address the underlying autoimmune condition. Ligand epitope antigen presentation system (L.E.A.P.S. ) conjugates are a peptide vaccine platform designed to modulate the immune response in an antigen-specific manner. LEAPS are composed of two peptide components, an immune cell binding ligand (ICBL) and a peptide (epitope) implicated in an infectious or autoimmune disease. The ICBLs include peptide J from human -2 microglobulin, with Th1-polarizing activity, and peptide derG (or G) from human MHC class II chain with Th2 polarizing activity. In mice with collagen-induced arthritis (CIA), a Th17-mediated disease, a J-collagen peptide conjugate reduced disease severity by suppressing
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical studies of PG70 LEAPS peptide vaccines for rheumatoid arthritis
- Peptide Vaccine for Experimental Autoimmune Myocarditis
- derG Immunostimulant Prevention/Treatment of HSV Disease
- Augmenting innate and vaccine immune response with der-G
- Not Available
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II
- Use of HIF-1alpha mRNA to Promote Pedicle Flap Healing.
- Development of novel genetic medicine approaches to treat orphan diseases
- A novel agent for preventing fatty degeneration of muscles in LGMD2B
- Bispecific biologic for rheumatoid arthritis therapy
Research funding history
7 SBIR/STTR records share this UEI (1998–2017). Reported award amounts total $2,223,665. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services